Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1541732 | 0.81 | MGLL (0.33) | MGLLGLA | |
| SCHEMBL863100 | 0.81 | MGLL (0.33) | MGLLGLA | |
| SCHEMBL4618888 | 0.74 | GLA (0.32) | MGLLGLA | |
| SCHEMBL18510166 | 0.72 | GLA (0.41) | MGLLGLA | |
| SCHEMBL30699 | 0.72 | GLA (0.41) | MGLLGLA | |
| SCHEMBL30779753 | 0.72 | GLA (0.41) | MGLLGLA | |
| SCHEMBL258692 | 0.71 | MGLL (0.36) | MGLLGLA | |
| SCHEMBL17430432 | 0.71 | MGLL (0.36) | MGLLGLA | |
| SCHEMBL9010906 | 0.70 | MGLL (0.33) | MGLLGLA | |
| Hydrogen Sulfide SCHEMBL28436920 | 0.70 | GLA (0.40) | MGLLGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104548118-A | Antibodized covalent modified poloxamer copolymer and preparation method and applications thereof | UNIV SOUTHEAST | 2015-04-29 | — | — | CN | claimed |
| WO-2010078376-A2 | FC-SPECIFIC POLYMER-CONJUGATED ANTIBODIES AND THEIR DIAGNOSTIC USE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| EP-0382781-B1 | COMPOSITION FOR TREATING CANCERS CHARACTERIZED BY OVER-EXPRESSION OF THE C-FMS PROTO-ONCOGENE | GENETICS INSTITUTE, INC. (US) | 1993-09-29 | — | — | EP | claimed |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TALLAC THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | Tallac Therapeutics, Inc. (US) | 2025-07-08 | — | — | US | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4257186-B1 | AFFINITY MEDICANT CONJUGATES | AF CHEMICALS LLC (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4257186-A2 | AFFINITY MEDICANT CONJUGATES | AF Chemicals LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3129357-B1 | AFFINITY MEDICANT CONJUGATES | AF CHEMICALS LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11359185-B2 | Antibody conjugates | VENTANA MEDICAL SYSTEMS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| WO-2002082078-A2 | ACTIVATED ENZYME-LINKED DETECTION SYSTEMS FOR DETECTING AND QUANTIFYING NUCLEID ACIDS, ANTIGENS ANTIBODIES AND OTHER ANALYTES | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002081739-A2 | NON-ENZYMATIC LIPOSOME-LINKED CLOSELY SPACED ARRAY ELECTRODES ASSAY (NEL-ELA) FOR DETECTING AND QUANTIFYING NUCLEIC ACIDS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002081738-A2 | SYSTEM AND METHOD FOR DETECTING AND QUANTIFYING NUCLEIC ACIDS USING COVALENT BINDING | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2002-10-17 | — | — | WO | disclosed |
| US-20020048598-A1 | INTERNALLY SUPPORTED LIPID VESICLE SYSTEMS | MALIK NAVID (GB) | 2002-04-25 | — | — | US | disclosed |
| US-20020006623-A1 | Compositions and methods for array-based genomic nucleic acid analysis of biological molecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-01-17 | — | — | US | disclosed |
| WO-2001041827-A1 | INTERNALLY SUPPORTED BIOMIMETIC MATERIALS AND COATINGS | MALIK NAVID (GB) | 2001-06-14 | — | — | WO | disclosed |
| EP-0998267-A1 | INTERNALLY SUPPORTED LIPID VESICLE SYSTEMS | Malik, Navid (GB) | 2000-05-10 | — | — | EP | disclosed |
| WO-1998056353-A1 | INTERNALLY SUPPORTED LIPID VESICLE SYSTEMS | MALIK NAVID (GB) | 1998-12-17 | — | — | WO | disclosed |
| EP-0382781-B1 | COMPOSITION FOR TREATING CANCERS CHARACTERIZED BY OVER-EXPRESSION OF THE C-FMS PROTO-ONCOGENE | GENETICS INSTITUTE, INC. (US) | 1993-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | MGLL 1795/4885GLA 3201/4885 |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | MGLL 1795/4885GLA 3201/4885 |
| US-20020048598-A1 | INTERNALLY SUPPORTED LIPID VESICLE SYSTEMS | STARD3, CHMP4B, EXOSC10 | MGLL 6/4885GLA 3787/4885 |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TYMP, DUT, PAICS | MGLL 4149/4885GLA 3566/4885 |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | UNG, DUT, TYMP | MGLL 4778/4885GLA 2778/4885 |
| US-20020006623-A1 | Compositions and methods for array-based genomic nucleic acid analysis of biological molecules | XRN2, XPA, XRCC6 | MGLL 3642/4885GLA 2045/4885 |
| US-11359185-B2 | Antibody conjugates | BCR, CD2BP2, EPCAM | MGLL 3100/4885GLA 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.